October 16, 2007 – Tomophase Corporation announced that it will display the first cross-sectional images of excised human bronchial tissue using their proprietary optical coherence tomography (“OCT”) system at the CHEST meeting in Chicago, October 22nd through October 24th... The Tomophase OCT System enables the interventional pulmonologist to clearly visualize sub-epithelial tissue structures in the airway. The system, which is not yet FDA-approved, utilizes a near-infrared emitting probe in a catheter which is integrated with a conventional video bronchoscope... Tomophase' Press Release-
Blog Archive
-
▼
2007
(90)
-
▼
October
(27)
- Wyeth, Tygacil for the Treatment of Patients with ...
- Tomophase, First Cross-Sectional Images Of Human B...
- Poniard Pharmaceuticals, Orphan Medicinal Product...
- Pharmion , Phase 3 Study of Amrubicin in Small Cel...
- DEY, Clinical Trials for Perforomist™ Inhalation S...
- Altair Therapeutics Will Develop Antisense Drugs f...
- Telik, TELCYTA Clinical Development
- Abraxis Bioscience, Special Protocol Assessment fo...
- Critical Therapeutics, Phase III Trial of Zileuton...
- Cellestis, FDA Approval for Blood Test for Detecti...
- Threshold Pharmaceuticals would stop enrollment in...
- Oridion, New Smart Capnography System for Improved...
- Proteolix , Carfilzomib in Subjects with Relapsed ...
- Nektar Therapeutics, NKTR-102 (PEG-Irinotecan) in ...
- Broncus Technologies, Encouraging Results Reported...
- Exelixis, Phase II study of XL647 in Patients with...
- MediciNova Positive Phase IIa Clinical Study Resul...
- PTC Therapeutics, Phase 2 Results of PTC124 in Cys...
- Inspire, Phase 3 Cystic Fibrosis Trial
- MedImmune , Phase 2 Safety Data for Anti-RSV Antib...
- Gilead, Phase III Study of Aztreonam Lysine for In...
- Invacare , new Invacare® XPO2™ extremely portable ...
- development of NOV-002, Novelos' lead compound in ...
- Critical Therapeutics, Phase I Clinical Trial of t...
- Emphasys Medical, PMA Submission for Bronchial Val...
- Discovery Laboratories, Surfaxin Process Validatio...
- FASgen, Significant Milestone in Its Cancer Drug D...
-
▼
October
(27)